JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Apellis Pharmaceuticals Inc

Fermé

SecteurSoins de santé

28.6 1.89

Résumé

Variation du prix de l'action

24h

Actuel

Min

28.02

Max

28.89

Chiffres clés

By Trading Economics

Revenu

50M

-42M

Ventes

12M

178M

Marge bénéficiaire

-23.615

Employés

705

EBITDA

50M

-30M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+28.14% upside

Dividendes

By Dow Jones

Prochains Résultats

30 oct. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.2B

3.6B

Ouverture précédente

26.71

Clôture précédente

28.6

Sentiment de l'Actualité

By Acuity

34%

66%

108 / 371 Classement par Healthcare

Apellis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 oct. 2025, 20:49 UTC

Résultats

Correction to Thermo Fisher Article on Oct. 22

23 oct. 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 oct. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 oct. 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 oct. 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 oct. 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23 oct. 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 oct. 2025, 22:49 UTC

Acquisitions, Fusions, Rachats

How Trump Sparked a New Era of State Capitalism -2-

23 oct. 2025, 22:49 UTC

Acquisitions, Fusions, Rachats

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 oct. 2025, 22:17 UTC

Résultats

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 oct. 2025, 21:41 UTC

Résultats

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 oct. 2025, 21:05 UTC

Résultats

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 oct. 2025, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

23 oct. 2025, 20:50 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

23 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 oct. 2025, 20:35 UTC

Résultats

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 oct. 2025, 20:28 UTC

Résultats

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 oct. 2025, 20:15 UTC

Market Talk
Résultats

Global Commodities Roundup: Market Talk

23 oct. 2025, 20:10 UTC

Résultats

Newmont Mining 3Q Adj EPS $1.71

23 oct. 2025, 20:10 UTC

Résultats

Newmont Mining 3Q Sales $5.52B

23 oct. 2025, 20:10 UTC

Résultats

Newmont Mining 3Q EPS $1.67

23 oct. 2025, 20:09 UTC

Résultats

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 oct. 2025, 20:07 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

23 oct. 2025, 20:07 UTC

Market Talk
Résultats

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 oct. 2025, 20:07 UTC

Résultats

Blackstone Looks to IPOs for Investment Exits -- Update

23 oct. 2025, 20:05 UTC

Résultats

Intel 3Q Gross Margin 38.2% >INTC

23 oct. 2025, 20:04 UTC

Résultats

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 oct. 2025, 20:04 UTC

Résultats

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 oct. 2025, 20:04 UTC

Résultats

Intel: 4Q Guidance Excludes Altera >INTC

23 oct. 2025, 20:04 UTC

Résultats

Intel Sees 4Q Adj EPS 8c >INTC

Comparaison

Variation de prix

Apellis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

28.14% hausse

Prévisions sur 12 Mois

Moyen 36.06 USD  28.14%

Haut 60 USD

Bas 18 USD

Basé sur 17 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

17 ratings

10

Achat

6

Maintien

1

Vente

Sentiment

By Acuity

108 / 371Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
help-icon Live chat